4.7 Article

Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy

期刊

JCI INSIGHT
卷 2, 期 1, 页码 -

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.89462

关键词

-

资金

  1. Japan Science and Technology Agency (JST)
  2. Ministry of Education, Culture, Sports, and Technology of Japan
  3. Japan Society for the Promotion of Science (JSPS) (JSPS KAKENHI) [JP24790734, JP26253006, JP15H05899, JP15H0589711]
  4. Japan Agency for Medical Research and Development (AMED) [16gm0710002h0304]
  5. Ono Medical Research Foundation
  6. Daiichi Sankyo Foundation of Life Science
  7. Grants-in-Aid for Scientific Research [26114005, 15H05897, 26293050, 15H05978, 25111005, 15K14947, 15K15304, 26253083] Funding Source: KAKEN

向作者/读者索取更多资源

Hypertrophic cardiomyopathy (HCM) is a common heart disease with a prevalence of 1 in 500 in the general population. Several mutations in genes encoding cardiac proteins have been found in HCM patients, but these changes do not predict occurrence or prognosis and the molecular mechanisms underlying HCM remain largely elusive. Here we show that cardiac expression of vacuolar protein sorting 34 (Vps34) is reduced in a subset of HCM patients. In a mouse model, muscle-specific loss of Vps34 led to HCM-like manifestations and sudden death. Vps34-deficient hearts exhibited abnormal histopathologies, including myofibrillar disarray and aggregates containing alpha B-crystallin (CryAB). These features result from a block in the ESCRT-mediated proteolysis that normally degrades K63-polyubiquitinated CryAB. CryAB deposition was also found in myocardial specimens from a subset of HCM patients whose hearts showed decreased Vps34. Our results identify disruption of the previously unknown Vps34-CryAB axis as a potentially novel etiology of HCM.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据